Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the child ADHD research overview.
Short answer. You cannot reliably evaluate stimulant medication from memory. The MTA Cooperative Group (1999) established the strongest evidence base in child psychiatry for stimulant benefit at the population level, but at the household level the question "is this dose helping this child at this stage" is an observation question that requires structured weekly data. Track 3–5 specific markers — on-task minutes during homework, number of morning prompts, meltdowns per week, sleep onset, appetite — for at least six weeks before any medication decision. Bring the data to the prescriber. The decision then moves from "I think it's helping" to "here is what changed and when."
Stimulant medication has the largest single evidence base in child psychiatry. The MTA Cooperative Group's 1999 trial established that medication management — when carefully titrated — outperformed community-care medication and combined well with behavioural treatment for functional outcomes. The AAP Clinical Practice Guideline (Wolraich et al., 2019) endorses stimulants as first-line pharmacological treatment for ADHD in children 6 and older, alongside behavioural parent training.
What the same literature is also explicit about: titration is a data-driven process. The MTA medication algorithm involved structured weekly ratings from parents and teachers, dose adjustments based on those ratings, and side-effect monitoring against a checklist. The "carefully titrated" arm outperformed community care in part because community care was titrated by impression. Pelham & Fabiano (2008) reach the same conclusion from the behavioural side: parent and teacher rating scales detect medication response that parental impression misses.
The implication is uncomfortable but important: the evidence base for stimulant benefit assumes structured measurement. Without it, you are running an intervention whose efficacy has been demonstrated under conditions you are not reproducing.
When parents ask "is the medication helping?" they almost always mean one of three things:
1. A specific behaviour has not changed. "He still melts down at homework" — but they have no data on whether the meltdowns are shorter, less frequent, or less intense. 2. A side effect is visible and the benefit is not. Reduced appetite, sleep onset delay, or emotional flatness are all observable in real time. Improvements in attention are not. 3. The first week was dramatic and then things plateaued. This is the predicted pattern, not evidence of failure — but it is widely misread.
In each case the underlying issue is the same: the cost of medication is salient day to day; the benefit shows up as a frequency shift that is invisible without measurement.
Pelham & Fabiano (2008) and the MTA medication algorithm both rely on a small set of ratings that detect stimulant response. A practical version for parents:
Time from sitting down to first off-task break. Track to the minute, weekly. This is the single marker most sensitive to stimulant dose response in school-aged children.
How many separate verbal prompts before the child is dressed, fed, has shoes on, and is at the door. Count, weekly average.
A meltdown is operationalised as an emotional escalation lasting more than 5 minutes that requires adult intervention. Count, weekly.
Minutes from lights-out to actually asleep. Stimulants commonly delay sleep onset; this is the most reliable side-effect marker.
Binary or three-point rating from school lunchbox returns. Reduced appetite is the most common stimulant side effect.
These five markers together cover both the targeted benefit (markers 1–3) and the most common side effects (markers 4–5). Six weeks of weekly data on these is enough to support a medication decision; less than that is impression dressed up as data.
The AAP and AACAP guidelines both treat the medication review as a structured, data-driven encounter. A useful packet:
1. The five weekly markers in a simple grid covering the last 6 weeks. 2. A side-effect note — sleep onset, appetite, mood, tics, headaches, cardiovascular symptoms. 3. One concrete question. "Should we adjust the dose?" "Should we add an afternoon booster?" "Should we switch from methylphenidate to amphetamine class?" Specific questions get specific answers; "is it working" gets reassurance.
Most prescribing decisions improve substantially when the parent arrives with structured data instead of impressions. This is the single most useful preparation any parent can do for a medication review, and it is the missing instrumentation that separates community-care titration from MTA-grade titration.
---
Unseen Progress publishes long-form caregiver research. See the full child ADHD research overview for the complete framework.